Norethindrone Acetate

Phase 3Small molecule

WWatson Pharmaceuticals

Norethindrone Acetate is one of 93 small molecule programs targeting Contraception. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ContraceptionActive, not recruiting

Breast CancerActive, not recruiting

EndometriosisActive, not recruiting

ContraceptionPhase 3

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

EndometriosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Halaven

Eisai

Preclinical

38 3

Norethindrone Acetate

WWatson Pharmaceuticals

Phase 3

1 4

MS Contin

Merck & Co.

Preclinical

2 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Zinecard

CChildren's Oncology Group

Preclinical

2 8

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 9

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—10

Zoladex

Luye Pharma Group Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Recruiting

Heavy Menstrual Bleeding

NCT05916469

Clinical

Trials by Indication[1]

Endometriosis6 trials

The Effect of Dienogest vs. Norethindrone Acetate Treatment in Endometriosis

Completed·UUludag University·N/A·NCT05476172·70 enrolled

Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis

Terminated·MMilton S. Hershey Medical Center·Phase 3·NCT03970330·9 enrolled

IUD and Norethindrone Acetate for Treatment of Endometriosis

Withdrawn·—·Phase 2·NCT04948489

Show 3 more trials

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

Unknown status·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 3·NCT00458458·112 enrolled

Cannabidiol and Management of Endometriosis Pain

Terminated·MMilton S. Hershey Medical Center·Phase 3·NCT04527003·12 enrolled

Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study

Completed·—·Phase 2·NCT02542410·10 enrolled

Contraception2 trials

Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception

Completed·WWatson Pharmaceuticals·Phase 3·NCT01140217·1,659 enrolled

The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception

Completed·UUniversity of Southern California·N/A·NCT01667978·35 enrolled

Heavy Menstrual Bleeding1 trial

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

Recruiting·OOregon Health and Science University··NCT05916469·300 enrolled

Bleeding1 trial

Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant

Completed·NNorton Healthcare·N/A·NCT02353247·88 enrolled

Breast Cancer1 trial

Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer

Completed·RRegional Oncologic Center·Phase 3·NCT00003771·1,300 enrolled

2 more indications

Metabolism1 trial

Metabolism of 0.35mg Norethindrone vs 5mg Norethindrone Acetate

Completed·MMilton S. Hershey Medical Center·Phase 4·NCT05294341·6 enrolled

Prolonged1 trial

Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™

Terminated·—·Phase 4·NCT04676061·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Norethindrone Acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Norethindrone Acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Norethindrone Acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Watson Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: WWatson Pharmaceuticals

Norethindrone Acetate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Endometriosis6 trials

Contraception2 trials

Heavy Menstrual Bleeding1 trial

Bleeding1 trial

Breast Cancer1 trial

Metabolism1 trial

Prolonged1 trial

References

Drug Info

Quick Facts

Related News